SPCs cannot be based on a medical devices certificate"
Paul England reports on the UKIPO's finding that SPC protection may not be based on a medical devices certificate.
SPC protection based on "subject-matter of the invention"
Paul England reports on the recent CJEU ruling in Actavis and Boehringer. More 
A Swiss MA is the "first authorisation" for the purpose of an SPC
We explain the relationship between Swiss marketing authorisations and the SPC Regulation. More
Calculating SPC term
This tool explains how the term of an SPC is calculated with respect to the term of the basic patent and the grant of the relevant marketing authorization.
Paediatric extensions to SPCs
Ed Vickers explains how compliance with an agreed paediatric investigation plan (PIP) will afford a six month extension to SPC protection on the relevant drug.
Conditions for obtaining an SPC
This article sets out the three key conditions for obtaining a supplementary protection certificate in the EU.
Supplementary protection certificates
The system of supplementary protection certificates ("SPCs") was introduced In 1993 as a means to effectively extend the patent term of protection for particular pharmaceutical products. It is intended to apply in circumstances where the term of a patent monopoly for a pharmaceutical products has been significantly eroded by the time taken for the grant of a marketing authorisation. This toolkit explains a number of key aspects of the SPC system and difficult issues that it has raised.